CSIMarket
 


Supernus Pharmaceuticals inc   (SUPN)
Other Ticker:  
 

Cumulative Supernus Pharmaceuticals Inc 's Quick Ratio for Trailing Twelve Months Period

SUPN's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

SUPN Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth -77.96 % -82.41 % 406.69 % 193.61 % 452.8 %
Y / Y Cash & cash equivalent Growth -75.76 % -93.15 % -81.28 % 35.81 % -11.73 %
Quick Ratio for Trailing Twelve Months Period 0.43 0.48 0.52 0.83 0.95
Total Ranking # 2341 # 2350 # 2390 # 2499 # 2399
Seq. Current Liabilities Growth 20.52 % -85.82 % 36.41 % -5.5 % -3.77 %
Seq. Cash & cash equivalent Growth 284.46 % -57.73 % -87.33 % 17.75 % 8.59 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Despite year on year decrease in Supernus Pharmaceuticals Inc 's average Current Liabilities to $125 millions, Quick Ratio for Trailing Twelve Months Period to 0.43 below company average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 398 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Supernus Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about SUPN
Quick Ratio SUPN in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 399
Sector # 743
S&P 500 # 1620


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
3.62 1.68 0.33
(Dec. 30, 2013)   (Sep 30 2023)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Entrada Therapeutics Inc   1.17 
Intelgenx Technologies Corp   1.16 
Vaccinex Inc   1.15 
Vbi Vaccines Inc  1.15 
Inflarx N v   1.15 
Harrow Inc   1.15 
Kineta Inc   1.14 
Aldeyra Therapeutics Inc   1.14 
Ainos Inc   1.14 
Evelo Biosciences Inc   1.11 
Nanobiotix S a   1.09 
Sellas Life Sciences Group Inc   1.07 
Evolus Inc   1.07 
Powerup Acquisition Corp   1.06 
Onconova Therapeutics inc   1.05 
Effector Therapeutics Inc   1.05 
Ani Pharmaceuticals Inc  1.05 
Paxmedica Inc   1.04 
Kintara Therapeutics Inc   1.04 
Molecular Templates inc   1.04 
Unicycive Therapeutics Inc   1.03 
Jazz Pharmaceuticals Plc  1.02 
Eterna Therapeutics Inc   1.01 
Morphosys Ag  1.01 
Rockwell Medical inc   1.00 
Promis Neurosciences inc   1.00 
Pfizer Inc  0.99 
Galapagos Nv  0.97 
Dar Bioscience Inc   0.97 
Nrx Pharmaceuticals Inc   0.96 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com